Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients – Early Results of a Phase II Trial

Glioblastoma Multiforme (GBM) is an aggressive primary brain neoplasm with dismal prognosis. Based on successful phase III trials, 60 Gy involved-field radiotherapy in 30 fractions over 6 weeks [Standard radiation therapy (RT)] with concurrent and adjuvant temozolomide is currently the standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Floyd, Scott R., Kasper, Ekkehard M., Uhlmann, Erik J., Fonkem, Ekokobe, Wong, Eric T., Mahadevan, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472503/
https://www.ncbi.nlm.nih.gov/pubmed/23087896
http://dx.doi.org/10.3389/fonc.2012.00122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472503/
https://www.ncbi.nlm.nih.gov/pubmed/23087896
http://dx.doi.org/10.3389/fonc.2012.00122

Ejemplares similares